GEHC

The Law Offices of Frank R. Cruz is investigating GE HealthCare Technologies for potential federal securities law violations. The investigation follows the company's April 2026 earnings report, which revealed a PDx supplier recall that impacted profit performance and margins, leading to reduced full-year EPS guidance and a 13.2% stock price decline. The company's CFO also stepped down in July 2026.

In a comparison of two medical products stocks, GE HealthCare Technologies (GEHC) emerges as the more attractive option for value investors compared to Stryker (SYK). GEHC has a higher Zacks Rank (#2 Buy vs #3 Hold), lower forward P/E ratio (12.97 vs 18.23), and a lower P/B ratio (2.63 vs 4.36), earning a Value grade of B compared to SYK's C grade.

GE HealthCare Technologies (GEHC) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company is expected to earn $4.93 per share for fiscal year 2026, with analysts steadily raising estimates over the past three months. The upgrade positions GEHC in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals.